Senior living provider The Pennant Group (NASDAQ: PNTG) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 30.1% year on year to $219.5 million. The company’s full-year revenue guidance of $870.2 million at the midpoint came in 2.1% above analysts’ estimates. Its GAAP profit of $0.20 per share was 17.9% below analysts’ consensus estimates.

Is now the time to buy PNTG? Find out in our full research report (it’s free).

StockStory’s Take

The Pennant Group’s second quarter was marked by strong revenue growth and a positive market response, reflecting management’s focus on operational execution and strategic expansion. CEO Brent Guerisoli credited performance to the company’s emphasis on leadership development, clinical quality, and margin improvement across its service lines. The quarter also benefited from Pennant’s ability to integrate new acquisitions and drive organic growth, especially within its home health and hospice operations. Management highlighted the resilience of its operating model despite challenges in reimbursement and regulatory pressures, with President John Gochnour noting, “Our excellent clinical and cultural performance continues to translate to record financial results.”

Looking ahead, Pennant’s guidance is shaped by its strategy of balancing organic growth with disciplined acquisitions and proactive operational adjustments in response to regulatory headwinds. Management signaled confidence in sustaining growth by leveraging a diversified revenue base and preparing for the integration of recently announced acquisitions, including the portfolio from UnitedHealth Group and Amedisys. CFO Lynette Walbom emphasized, “Our updated guidance incorporates current operations and organic growth, including additional expenses in anticipation of the transaction with UnitedHealth Group and Amedisys.” However, management also acknowledged persistent reimbursement uncertainties and the need to adapt cost structures and operational models as the regulatory landscape evolves.

Key Insights from Management’s Remarks

Management attributed the quarter’s performance to strong organic growth, improved operational quality, and effective integration of new acquisitions, while also highlighting ongoing challenges related to regulatory change and industry consolidation.

• Home Health organic expansion: The home health segment saw robust organic growth, driven by increased admissions and improved referral management at the local level. Management noted that home health revenue rose meaningfully as teams optimized care delivery and maintained high-quality standards, with Gochnour citing a “steady growth story” in mature markets.

• Hospice momentum and headwinds: The hospice business continued to deliver strong results, with notable increases in revenue and admissions. However, management flagged ongoing cap expense challenges in certain California operations, outlining a strategy to resolve these issues while sustaining underlying growth.

• Senior Living margin progress: Senior living operations benefited from improved occupancy rates and higher revenue per occupied room, attributed to efforts in pricing discipline and service quality. Management highlighted that these gains more than offset the wind-down of pandemic-era support programs, with positive momentum expected to continue as occupancy crosses the 80% threshold.

• Acquisition strategy accelerates: Pennant completed several acquisitions—including GrandCare Home Health and Red Mountain Senior Living—while preparing to close a significant portfolio purchase from UnitedHealth Group and Amedisys. Management described the acquisition in the Southeast as a “center of strength” with opportunities for scale and market penetration.

• Regulatory vigilance and advocacy: Management discussed the impact of the proposed 2026 home health rule, which could reduce aggregate payments to agencies. The team emphasized ongoing advocacy efforts and operational planning to mitigate the effects of potential reimbursement reductions, noting the diversified business model and preparation for various regulatory scenarios.

Drivers of Future Performance

Pennant’s outlook for the coming quarters centers on integrating recent acquisitions, optimizing existing operations, and managing regulatory risks that could impact both revenue growth and margins.

• Acquisition integration and scale: The planned addition of up to 50 home health and hospice agencies from UnitedHealth Group and Amedisys is expected to expand Pennant’s footprint in the Southeast, providing new market opportunities and potential operational synergies. Management underscored ongoing investments in leadership and shared services to facilitate a smooth transition and accelerate value capture.

• Regulatory headwinds and adaptation: The proposed 2026 home health rule presents a major risk, with management actively engaged in advocacy and contingency planning. Although traditional Medicare home health revenue is a minority of total revenue, potential cuts could affect both government and managed care contracts, prompting Pennant to prepare operational adjustments to maintain profitability.

• Margin improvement initiatives: Management aims to drive margin expansion in the second half of the year through operational efficiencies, reduced hospice cap expenses, and continued optimization of recent acquisitions. CFO Walbom indicated that higher occupancy and rate improvements in senior living, as well as contributions from new businesses, will be central to achieving margin targets.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will be watching (1) the pace and effectiveness of integrating the newly acquired UnitedHealth Group and Amedisys portfolio, (2) operational progress in improving margins—particularly in senior living and hospice segments, and (3) any updates on the final 2026 home health rule and Pennant’s adaptations to potential reimbursement changes. The trajectory of organic growth and further M&A activity will also remain key areas of focus.

The Pennant Group currently trades at $26.46, up from $22.27 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.